LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...
Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...
SCD seeks total returns with a primary focus on income, investing globally in companies with strong fundamentals and clear market advantages. The fund uses leverage to enhance returns, with interest ...
The Department of Health and Human Services (HHS), Office of Minority Health requests that the National Academies of Sciences, Engineering, and Medicine convene an ad hoc committee to develop a ...
Vertex unveiled long-term durability data for Casgevy, while Beam presented Phase I/II findings for its investigational base editor BEAM-101, building up to a BLA by late 2026. In a presentation set ...
SeaStar Medical (ICU) announces the receipt of a Breakthrough Device Designation, BDD, from the U.S. Food and Drug Administration’s, FDA, Center for Biologics Evaluation and Research, CBER, for the ...
A new study finds that preschool-aged children with sickle cell disease (SCD) who live in food deserts and have limited access to transportation are at greater risk for acute complications and ...
The global withdrawal of voxelotor (Oxbryta, Pfizer) has left clinicians who treat sickle cell disease (SCD) with the urgent task of reaching patients taking the medicine, while trying to understand ...
Sixteen patients dosed with Pfizer’s sickle cell disease drug Oxbryta® (voxelotor) in a pair of clinical trials have died, European regulators disclosed hours before Pfizer said it was voluntarily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback